More on BMY
Data
Financials
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $56.90 |
|
|||
| Open | $57.45 | ||||
| 52 Wk High | $77.12 | ||||
| 52 Wk Low | $49.03 | ||||
| Day High | $57.60 | ||||
| Day Low | $56.77 | ||||
| P/E | 37.10 | ||||
| EPS | $1.54 | ||||
| Volume | 7,839,148 | ||||
- Leerink highlights drug demand rebound after Memorial Day
- Bristol-Myers Squibb (BMY) call put ratio 6.8 calls to 1 put with a focus on spreader of 8244 contracts of June and July 57.50 calls
- Mariska Hargitay partners with Bristol Myers Squibb for myeloma awareness
- Mariska Hargitay Partners with Bristol Myers Squibb for “Investigating Myeloma” Awareness Campaign to Honor Her Father 20 Years After Losing Him to the Disease
- Form 4 BRISTOL MYERS SQUIBB CO For: Jun 03 Filed by: Short Bartie Wendy
- Form 11-K BRISTOL MYERS SQUIBB CO For: Dec 31
- Form 11-K BRISTOL MYERS SQUIBB CO For: Dec 31
- Form 11-K BRISTOL MYERS SQUIBB CO For: Dec 31
- Arcus Biosciences partners with Bristol Myers Squibb on kidney cancer trial
- Arcus Biosciences Announces Clinical Trial Collaboration and Supply Agreement to Evaluate Casdatifan in Combination with PD‑L1/VEGF‑A Bispecific Immunomodulator to Treat Kidney Cancer
Entities mentioned with BMY
- Twitter | View Related Stories »
- FDA | View Related Stories »
- Earnings | View Related Stories »
- Definitive Agreement | View Related Stories »
- PDUFA | View Related Stories »
- ARK | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- Maynard Um | View Related Stories »
- Show More...
